CN107158322A - 一种用于痛风、软组织损伤、风湿疼痛的制剂及其制备方法 - Google Patents
一种用于痛风、软组织损伤、风湿疼痛的制剂及其制备方法 Download PDFInfo
- Publication number
- CN107158322A CN107158322A CN201710408826.5A CN201710408826A CN107158322A CN 107158322 A CN107158322 A CN 107158322A CN 201710408826 A CN201710408826 A CN 201710408826A CN 107158322 A CN107158322 A CN 107158322A
- Authority
- CN
- China
- Prior art keywords
- parts
- preparation
- gout
- soft tissue
- tissue injury
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000002193 Pain Diseases 0.000 title claims abstract description 87
- 238000002360 preparation method Methods 0.000 title claims abstract description 69
- 201000005569 Gout Diseases 0.000 title claims abstract description 49
- 208000026137 Soft tissue injury Diseases 0.000 title claims abstract description 42
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 31
- 235000003392 Curcuma domestica Nutrition 0.000 claims abstract description 30
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 30
- 235000013976 turmeric Nutrition 0.000 claims abstract description 30
- 239000002994 raw material Substances 0.000 claims abstract description 21
- 241000244987 Daiswa polyphylla Species 0.000 claims abstract description 18
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 17
- 241000601164 Clematis orientalis Species 0.000 claims abstract description 17
- 244000111489 Gardenia augusta Species 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 17
- 241000031023 Amana edulis Species 0.000 claims abstract description 16
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 16
- 235000018958 Gardenia augusta Nutrition 0.000 claims abstract description 16
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 15
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 60
- 239000003814 drug Substances 0.000 claims description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- 239000000341 volatile oil Substances 0.000 claims description 21
- 239000000463 material Substances 0.000 claims description 19
- 239000006071 cream Substances 0.000 claims description 18
- 239000007921 spray Substances 0.000 claims description 17
- 239000000706 filtrate Substances 0.000 claims description 14
- 230000001954 sterilising effect Effects 0.000 claims description 14
- 238000001914 filtration Methods 0.000 claims description 11
- 238000002386 leaching Methods 0.000 claims description 8
- 239000004744 fabric Substances 0.000 claims description 7
- 239000000346 nonvolatile oil Substances 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 239000006228 supernatant Substances 0.000 claims description 7
- 238000005292 vacuum distillation Methods 0.000 claims description 4
- 238000007654 immersion Methods 0.000 claims description 2
- 229940040145 liniment Drugs 0.000 claims description 2
- 239000000865 liniment Substances 0.000 claims description 2
- 229940098465 tincture Drugs 0.000 claims description 2
- 239000008280 blood Substances 0.000 abstract description 34
- 210000004369 blood Anatomy 0.000 abstract description 33
- 230000000694 effects Effects 0.000 abstract description 22
- 230000008961 swelling Effects 0.000 abstract description 15
- 230000017531 blood circulation Effects 0.000 abstract description 14
- 230000001737 promoting effect Effects 0.000 abstract description 13
- 238000004519 manufacturing process Methods 0.000 abstract description 9
- 230000004087 circulation Effects 0.000 abstract description 8
- 210000003205 muscle Anatomy 0.000 abstract description 8
- 238000009472 formulation Methods 0.000 abstract description 5
- 239000000203 mixture Substances 0.000 abstract description 5
- 231100000252 nontoxic Toxicity 0.000 abstract description 3
- 230000003000 nontoxic effect Effects 0.000 abstract description 3
- 238000001816 cooling Methods 0.000 abstract description 2
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 238000011282 treatment Methods 0.000 description 23
- 208000024891 symptom Diseases 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 201000010099 disease Diseases 0.000 description 17
- 210000004185 liver Anatomy 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 206010042674 Swelling Diseases 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 230000006378 damage Effects 0.000 description 12
- 239000000796 flavoring agent Substances 0.000 description 10
- 235000019634 flavors Nutrition 0.000 description 10
- 210000003734 kidney Anatomy 0.000 description 10
- 206010067484 Adverse reaction Diseases 0.000 description 9
- 208000006820 Arthralgia Diseases 0.000 description 9
- 230000006838 adverse reaction Effects 0.000 description 9
- 208000014674 injury Diseases 0.000 description 9
- 230000010415 tropism Effects 0.000 description 9
- 208000011580 syndromic disease Diseases 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 6
- 238000004821 distillation Methods 0.000 description 6
- 210000001503 joint Anatomy 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 239000003435 antirheumatic agent Substances 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- 210000004872 soft tissue Anatomy 0.000 description 5
- 206010013935 Dysmenorrhoea Diseases 0.000 description 4
- 201000001431 Hyperuricemia Diseases 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 230000000172 allergic effect Effects 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000003127 knee Anatomy 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 206010038743 Restlessness Diseases 0.000 description 3
- 208000004078 Snake Bites Diseases 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 210000003041 ligament Anatomy 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 231100000862 numbness Toxicity 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 241000382455 Angelica sinensis Species 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 208000034656 Contusions Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010014080 Ecchymosis Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000006877 Insect Bites and Stings Diseases 0.000 description 2
- 206010023232 Joint swelling Diseases 0.000 description 2
- 206010024453 Ligament sprain Diseases 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 206010042345 Subcutaneous haematoma Diseases 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 208000026816 acute arthritis Diseases 0.000 description 2
- 210000003423 ankle Anatomy 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- NCEXYHBECQHGNR-UHFFFAOYSA-N chembl421 Chemical compound C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 238000010579 first pass effect Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000008407 joint function Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 201000003068 rheumatic fever Diseases 0.000 description 2
- 210000002832 shoulder Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010051728 Bone erosion Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000205571 Caulophyllum Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 241001256368 Clematis chinensis Species 0.000 description 1
- 241000725146 Clematis hexapetala Species 0.000 description 1
- 241000915582 Clematis manshurica Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000846172 Cremastra appendiculata Species 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 208000037039 Monarthritis Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000123069 Ocyurus chrysurus Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 241001250598 Pleione bulbocodioides Species 0.000 description 1
- 241001457446 Pleione yunnanensis Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102100033717 Retroviral-like aspartic protease 1 Human genes 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 241000593989 Scardinius erythrophthalmus Species 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 101710188689 Small, acid-soluble spore protein 1 Proteins 0.000 description 1
- 101710188693 Small, acid-soluble spore protein 2 Proteins 0.000 description 1
- 101710166422 Small, acid-soluble spore protein A Proteins 0.000 description 1
- 101710166404 Small, acid-soluble spore protein C Proteins 0.000 description 1
- 101710174019 Small, acid-soluble spore protein C1 Proteins 0.000 description 1
- 101710174017 Small, acid-soluble spore protein C2 Proteins 0.000 description 1
- 101710174574 Small, acid-soluble spore protein gamma-type Proteins 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 240000003248 Zanthoxylum nitidum Species 0.000 description 1
- 208000011279 abdominal lump Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000002310 elbow joint Anatomy 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 208000003512 furunculosis Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 210000001255 hallux Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 208000006278 hypochromic anemia Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000009916 joint effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000008807 pathological lesion Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- SBNFWQZLDJGRLK-UHFFFAOYSA-N phenothrin Chemical compound CC1(C)C(C=C(C)C)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 SBNFWQZLDJGRLK-UHFFFAOYSA-N 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 235000019991 rice wine Nutrition 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000011865 skeletal system disease Diseases 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 210000001171 synovial bursa Anatomy 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 210000003857 wrist joint Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/716—Clematis (leather flower)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/758—Zanthoxylum, e.g. pricklyash
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种用于痛风、软组织损伤、风湿疼痛的制剂及其制备方法。所述制剂包括以下重量份的原料:威灵仙20‑40份、两面针20‑60份、山慈菇10‑30份、三七20‑40份、当归20‑60份、姜黄60‑100份、栀子20‑40份、红花10‑30份、重楼10‑30份。所述制剂具有清热凉血、祛风除湿、活血化瘀、舒筋活络、消肿止痛的功效,对痛风、软组织损伤、风湿疼痛有很好的疗效,使用方便、安全、无毒、无副作用。所述制剂制备方法工艺简单,生产成本低,耗能低,易实现工业化生产。
Description
技术领域
本发明属于药品领域,涉及一种中药制剂及其制备方法,特别涉及一种用于痛风、软组织损伤、风湿疼痛的制剂及其制备方法。
背景技术
痛风(gout)是嘌呤类物质代谢紊乱,血尿酸浓度持续增高导致尿酸盐结晶沉积软组织所致的一组代谢性疾病。临床上表现为高尿酸血症(hype-ruricemia)、痛风性急性关节炎、痛风石沉积、特征性慢性关节炎和关节炎畸形,常累及肾,引发慢性间质性肾炎和肾尿酸结石,痛风性关节炎常为该综合征的首发表现,严重者可出现关节致残。痛风的生化标志是高尿酸血症,与高血压、高血脂、动脉粥样硬化、肥胖、胰岛素抵抗的发生密切相关。近年来,痛风的发病率呈现上升趋势,已成为继糖尿病之后的第二大代谢类疾病,严重危害人类的健康。目前对痛风的治疗,临床上常用秋水仙碱、肾上腺糖皮质激素、别嘌呤醇等,这些药物虽能缓解急性关节炎及产生一定的降低血尿酸的作用,但不良反应较为明显。中医中药在安全性和有效性上有着较大的优势,因此在中医中药中寻求治疗痛风安全有效的药物和制剂是一种趋势,也符合临床诊治的需要。中医学中痛风有“痛风”“贼风”“痹”“历节”等病名。病因病机主要为肝、脾、肾功能失调,过食膏粱厚味,脾失健运或禀赋不足,肾升清降浊失司以致湿热浊毒内生,又兼外感风寒湿邪,侵袭经络,气血运行不畅,湿热痰浊痹阻经络,不通则痛。湿热证、痰瘀互结证、肝肾阴虚证、脾肾阳虚证、痰热内阻证、血瘀化热证、湿热瘀阻证、血瘀证为痛风病的常见类型。针对病因病机及辩证分型,痛风的中医治法主要有清热利尿、活血化瘀、祛风渗湿等,用药以清热药、活血化瘀药、利水渗湿药和祛风湿药为主。
软组织损伤是指由各种急性外伤或慢性劳损,以及自身疾病等原因造成机体的皮肤、皮下浅、深筋膜、肌肉、肌腱、腱鞘、韧带、关节囊、滑膜囊、椎间盘、周围神经血管等组织的病理损害,为骨伤科常见病。随着人们生活节奏的加快,软组织损伤的患者在高能量运动日益增多的今天不断增多。本病不仅给患者本人带来痛苦和不便,也给社会劳动生产造成了很大的损失,使得如何更好的治疗软组织损伤,如何提高治疗效果成为了医学界普遍关注的问题。目前对这类疾病的主要治疗方法,西医治疗有理疗,外用药治疗,封闭治疗、负压引流治疗、手术治疗等方法,但尚缺乏特效的治疗方法;中医治疗有中医内治法(药物内服)、中医药外治法,针灸推拿治疗等方法。软组织损伤属于中医学“伤筋”范畴,其主要病机是气滞血瘀,脉络不通,在治则上大多采用活血化瘀、舒筋活络、温经解表、消肿止痛、清热凉血等方药。
风湿性疾病(简称风湿病)是一组涉及肌肉骨骼系统、关节、关节周围软组织,并以疼痛症状为主的慢性疾病。风湿病成因复杂,至今未完全明了。一般认为,其发病是在遗传易感性的基础上,受性激素、环境因素、社会、生理、心理等因素相互作用下机体免疫功能紊乱而引起的慢性炎症性疾病。目前还没有一种特效药物能彻底根治风湿病,但根据其发病机制,通过阻滞不同关键环节,能有效缓解疾病进程,改善预后。西医治疗风湿病往往采用联合用药、对症治疗,目前常用的抗风湿药按其功能或作用靶点不同可分为6类:改善症状抗风湿药[非甾体抗炎药(NSAIDs)]、改善病情的抗风湿药(DMARDs)、糖皮质激素、生物制剂、多靶点抗风湿药、改善和增强体质抗风湿药。西药治疗风湿病效果非常不尽人意,治标不治本,顾此失彼,只能暂缓病人的症状,还带来了消化道溃疡、骨质疏松、库欣综合征等诸多副作用。中医认为,凡因邪气阻滞、经气不利导致的疾病均属于风湿痹症。其治疗主要从扶正祛邪、祛风散寒除湿、活血化瘀通络三个方面入手,所用中药以祛邪扶正类药物为主,以活血化瘀、通络止痛、补血益气、祛风除湿、补肝肾、强筋骨类药物为辅,治疗效果及预后有独特的优势。
对于上述三种病症的治疗方法,多采用“筋伤”的常用方及类似方的传统制剂。而这类制剂大多是口服制剂,外用贴剂,外用膏剂等,口服制剂由于首过效应使药效大大降低,副作用增加;外用膏剂常常出现过敏、皮疹,黏着汗毛、污染衣物等现象,给患者带来了不必要的麻烦,贴剂则在剥离时会出现疼痛感和难以洗脱的药物残留。巴布膏是一种最常用的外用贴膏剂,为药材提取物或化学药物与适宜的亲水性基质混合后,涂布在背衬材料上制成的贴膏剂。其载药量大,保湿性强,与皮肤的相容性好,耐老化,可以反复揭贴,随时终止给药,剂量准确,血药浓度平衡无峰谷现象,可减少毒副作用,在工业生产中无有机溶剂污染符合环保要求,它和传统贴剂的区别在于巴布膏基质是高性大分子材料调配。由于巴布膏对基质要求较高,载药量较大,所以多用于中药浸膏,而中药浸膏制作过程的复杂和繁琐并不能及时满足市场的需求。本发明针对以上所述问题研发出的一种能同时用于痛风、软组织损伤、风湿疼痛的中药外用制剂,具有毒副作用小、疗效好且作用持久的特点,目前,尚未见相关报道。
(1)威灵仙,为毛莨科植物威灵仙Clematis chinensis Osbeck、棉团铁线莲Clematis hexapetala Pall.或东北铁线莲Clematis manshurica Rupr.的干燥根和根茎。收载于《中国药典》2015年版:【性味与归经】辛、咸,温;归膀胱经。【功能与主治】祛风湿,通经络。用于风湿痹痛,肢体麻木,筋脉拘挛,屈伸不利。
(2)两面针,为芸香科植物两面针Zanthoxylum nitidum(Roxb.)DC.的干燥根。收载于《中国药典》2015年版:【性味与归经】苦、辛,平有小毒;归肝、胃经。【功能与主治】活血化瘀,行气止痛,祛风通铬,解毒消肿。用于秩扑损伤,胃痛,牙痛,风湿痹痛,毒蛇咬伤;外治烧烫伤。
(3)山慈菇,为兰科植物杜鹃兰Cremastra appendiculata(D.Don)Makino、独蒜兰Pleione bulbocodioides(Franch.)Rolfe或云南独蒜兰Pleione yunnanensis Rolfe的干燥假鳞茎。收载于《中国药典》2015年版:【性味与归经】甘、微辛,凉。归肝、脾经。【功能与主治】清热解毒,化痰散结。用于痈肿疔毒,瘰疬痰核,蛇虫咬伤,癍瘕痞块。
(4)三七,为五加科植物三七Panax notoginseng(Burk.)F.H.Chen的干燥根和根茎。收载于《中国药典》2015年版:【性味与归经】甘、微苦,温。归肝、胃经。【功能与主治】散瘀止血,消肿定痛。用于咯血,吐血,衄血,便血,崩漏,外伤出血,胸腹刺痛,跌扑肿痛。
(5)当归,为伞形科植物当归Angelica sinensis(Oliv.)Diels的干燥根。收载于《中国药典》2015年版:【性味与归经】甘、辛,温。归肝、心、脾经。【功能与主治】补血活血,调经止痛,润肠通便。用于血虚萎黄,眩晕心悸,月经不调,经闭痛经,虚寒腹痛,风湿痹痛,跌扑损伤,痈疽疮疡,肠燥便秘。酒当归活血通经。用于经闭痛经,风湿痹痛,跌扑损饬。
(6)姜黄,为姜科植物姜黄Curcuma Longa L.的干燥根茎。收载于《中国药典》2015年版:【性味与归经】辛、苦,温。归脾、肝经。【功能与主治】破血行气,通经止痛。用于胸胁刺痛,胸搏心痛,痛经经闭,癥瘕,风湿肩臂疼痛,跌扑肿痛。
(7)栀子,为茜草科植物栀子Gardenia jasmioides的干燥成熟果实。收载于《中国药典》2015年版:【性味与归经】苦,寒。归心、肺、三焦经。【功能与主治】泻火除烦,清热利湿,凉血解毒;外用消肿止痛。用于热病心烦,湿热黄疸,淋证涩痛,血热吐衄,目赤肿痛,火毒疮疡;外治扭挫伤痛。
(8)红花,为菊科植物红花Carthamus tinctorius L.的干燥花。收载于《中国药典》2015年版:【性味与归经】辛,温。归心、肝经。【功能与主治】活血通经,散瘀止痛。用于经闭,痛经,恶露不行,癥瘕痞块,胸痹心痛,瘀滞腹痛,胸胁剌痛,跌扑损伤,疮疡肿痛。
(9)重楼,为百合科植物云南重楼Paris polyphylla Smithvar.yunnanensis(Franch.)Hand.-Mazz.或七叶一枝花Parispolyphylla Smith var.chinensis(Franch.)Hara的干燥根茎。收载于《中国药典》2015年版:【性味与归经】苦,微寒;有小毒。归肝经。【功能与主治】清热解毒,消肿止痛,凉肝定惊。用于疔疮痈肿,咽喉肿痛,蛇虫咬伤,跌扑伤痛,惊风抽搐。
以上背景技术内容的公开仅用于辅助理解本发明的发明构思及技术方案,其并不必然属于本专利申请的现有技术,在没有明确的证据表明上述内容在本专利申请的申请日已经公开的情况下,上述背景技术不应当用于评价本申请的新颖性和创造性。
发明内容
本发明目的在于提供一种用于痛风、软组织损伤、风湿疼痛的制剂及其制备方法,以解决现有技术中存在的西药治疗痛风、风湿类疾病副作用大,治疗软组织损伤尚缺乏特效的治疗方法等问题。
本发明以中药为原料,通过科学合理配制,制成一种中药外用制剂,所述制剂具有祛风通络、活血止痛的功效,使用方便、安全、无毒、无副作用,并且制备方法简单,生产成本低,耗能低,易实现工业化生产。
本发明采用的技术方案如下:
一种用于痛风、软组织损伤、风湿疼痛的制剂,包括以下重量份的原料:威灵仙20-40份、两面针20-60份、山慈菇10-30份、三七20-40份、当归20-60份、姜黄60-100份、栀子20-40份、红花10-30份、重楼10-30份。
以上所述用于痛风、软组织损伤、风湿疼痛的制剂,优选包括以下重量份的原料:威灵仙25-35份、两面针30-50份、山慈菇15-25份、三七25-35份、当归30-50份、姜黄70-90份、栀子25-35份、红花15-25份、重楼15-25份。
以上所述用于痛风、软组织损伤、风湿疼痛的制剂,最佳优选包括以下重量份的原料:威灵仙30份、两面针40份、山慈菇20份、三七30份、当归40份、姜黄80份、栀子30份、红花20份、重楼20份。
以上所述的用于痛风、软组织损伤、风湿疼痛的制剂,可制备成喷剂、搽剂、酊剂等外用制剂,最佳优选制备成喷剂。
以上所述的用于痛风、软组织损伤、风湿疼痛的制剂,在制备用于痛风、软组织损伤、风湿疼痛的药物中的用途。
一种以上所述的用于痛风、软组织损伤、风湿疼痛的制剂制备成喷剂的制备方法,包括以下步骤:
S1:按以下重量份称取原料:威灵仙20-40份、两面针20-60份、山慈菇10-30份、三七20-40份、当归20-60份、姜黄60-100份、栀子20-40份、红花10-30份、重楼10-30份;
S2:取步骤S1称量好的当归及姜黄药材,粉碎成10目后,投入多功能提取罐内,加3-5倍量水浸泡2-3h,减压蒸馏至无挥发油产生,收集挥发油;
S3:取步骤S1称量好的其他药材投入到步骤S2的当归、姜黄药渣中,加原料组分总重量的5-10倍量水,煎煮2-3次,每次1-3h,过滤,合并滤液;
S4:将步骤S3的滤液浓缩至相对密度在60-65℃为1.03-1.07的清膏,加入与清膏等量的95%乙醇,静置,滤取上清液回收乙醇浓缩至相对密度在60-65℃为1.05-1.10的浸膏;
S5:取步骤S2制得的挥发油加乙醇溶解后,搅拌20-40min,备用;
S6:取步骤S4制得的浸膏置于配料罐中,加入步骤S5的挥发油乙醇液,搅拌均匀,最后加水至配制量,搅拌20-30min,取出,过滤,灭菌,装入经过灭菌的雾化喷头容器,即得。
进一步地,步骤S2所述减压蒸馏温度为60-75℃,蒸馏压力为(-0.06MPa)-(-0.08Mpa);步骤S4所述加入乙醇后静置时间为12-24h;步骤S6所述过滤步骤用100目滤布过滤。
与现有技术相比,本发明具有以下有益效果:
1.本发明用于痛风、软组织损伤、风湿疼痛的制剂,所用中药均收载于《中国药典》2015年版,通过现代科学合理配方,组方严谨,药少力专。方中威灵仙,具祛风湿,通经络之功,为君药。两面针活血化瘀,行气止痛,祛风通络,解毒消肿;山慈菇清热解毒,化痰散结;三七散瘀止血,消肿定痛;当归补血活血,调经止痛;四药合用助君药祛风湿,通经络之功,为臣药。姜黄破血行气,通经止痛;栀子泻火除烦,清热利湿,凉血解毒,消肿止痛;二者合用为佐药。红花活血通经,散瘀止痛;重楼清热解毒,消肿止痛,凉肝定惊;二合用为佐药。诸药合用共凑清热凉血、祛风除湿、活血化瘀、舒筋活络、消肿止痛之功,对痛风、软组织损伤、风湿疼痛有很好的疗效,治疗总有效率分别为94.5%、100%、92.4%。
2.本发明所述制剂为中药外用制剂,避免了口服给药存在的首关效应,也避免了传统的外用贴剂在剥离时会出现疼痛感和难以洗脱的药物残留,使用方便、安全、无毒、无副作用。
3.本发明所述制剂制备方法简单,对生产设备无特殊要求、容易操作、耗能低、省时、生产成本低,容易实现工业化生产。
具体实施方式
下面结合具体实施例对本发明作进一步描述,但不限制本发明的保护范围和应用范围:
一、用于治疗痛风、软组织损伤、风湿疼痛的制剂制备成喷剂的制备方法
实施例1
一种用于痛风、软组织损伤、风湿疼痛的制剂制备成喷剂的制备方法,包括以下步骤:
S1:按以下重量份称取原料:威灵仙20kg、两面针20kg、山慈菇10kg、三七20kg、当归20kg、姜黄60kg、栀子20kg、红花10kg、重楼10kg;
S2:取步骤S1称量好的当归及姜黄药材,粉碎成10目后,投入多功能提取罐内,加3倍量水浸泡3h,-0.08Mpa压力下60℃蒸馏至无挥发油产生,收集挥发油;
S3:取步骤S1称量好的其他药材投入到步骤S2的当归、姜黄药渣中,加原料组分总重量5倍量水,煎煮3次,每次1h,过滤,合并滤液;
S4:将步骤S3的滤液浓缩至相对密度在60℃为1.03的清膏,加入与清膏等量的95%乙醇,静置18h,滤取上清液回收乙醇浓缩至相对密度在60℃为1.05的浸膏;
S5:取步骤S2制得的挥发油加乙醇溶解后,搅拌20min,备用;
S6:取步骤S4制得的浸膏置于配料罐中,加入步骤S5的挥发油乙醇液,搅拌均匀,最后加水至配制量,搅拌20min,取出,100目滤布过滤,灭菌,装入经过灭菌的雾化喷头容器,即得。
实施例2
一种用于痛风、软组织损伤、风湿疼痛的制剂制备成喷剂的制备方法,包括以下步骤:
S1:按以下重量份称取原料:威灵仙40kg、两面针60kg、山慈菇30kg、三七40kg、当归60kg、姜黄100kg、栀子40kg、红花30kg、重楼30kg;
S2:取步骤S1称量好的当归及姜黄药材,粉碎成10目后,投入多功能提取罐内,加5倍量水浸泡2h,-0.06Mpa压力下75℃蒸馏至无挥发油产生,收集挥发油;
S3:取步骤S1称量好的其他药材投入到步骤S2的当归、姜黄药渣中,加原料组分总重量10倍量水,煎煮2次,每次3h,过滤,合并滤液;
S4:将步骤S3的滤液浓缩至相对密度在65℃为1.07的清膏,加入与清膏等量的95%乙醇,静置24h,滤取上清液回收乙醇浓缩至相对密度在65℃为1.10的浸膏;
S5:取步骤S2制得的挥发油加乙醇溶解后,搅拌40min,备用;
S6:取步骤S4制得的浸膏置于配料罐中,加入步骤S5的挥发油乙醇液,搅拌均匀,最后加水至配制量,搅拌30min,取出,100目滤布过滤,灭菌,装入经过灭菌的雾化喷头容器,即得。
实施例3
一种用于痛风、软组织损伤、风湿疼痛的制剂制备成喷剂的制备方法,包括以下步骤:
S1:按以下重量份称取原料:威灵仙25kg、两面针30kg、山慈菇15kg、三七25kg、当归30kg、姜黄70kg、栀子25kg、红花15kg、重楼15kg;
S2:取步骤S1称量好的当归及姜黄药材,粉碎成10目后,投入多功能提取罐内,加4倍量水浸泡2.5h,-0.07Mpa压力下68℃蒸馏至无挥发油产生,收集挥发油;
S3:取步骤S1称量好的其他药材投入到步骤S2的当归、姜黄药渣中,加水煎煮2次,第一次加原料组分总重量8倍量水,煎煮2h,第二次加过滤原料组分总重量7倍量水,煎煮2h,合并滤液;
S4:将步骤S3的滤液浓缩至相对密度在62℃为1.04的清膏,加入与清膏等量的95%乙醇,静置20h,滤取上清液回收乙醇浓缩至相对密度在62℃为1.06的浸膏;
S5:取步骤S2制得的挥发油加乙醇溶解后,搅拌30min,备用;
S6:取步骤S4制得的浸膏置于配料罐中,加入步骤S5的挥发油乙醇液,搅拌均匀,最后加水至配制量,搅拌20min,取出,100目滤布过滤,灭菌,装入经过灭菌的雾化喷头容器,即得。
实施例4
一种用于痛风、软组织损伤、风湿疼痛的制剂制备成喷剂的制备方法,包括以下步骤:
S1:按以下重量份称取原料:威灵仙55kg、两面针50kg、山慈菇25kg、三七35kg、当归50kg、姜黄90kg、栀子35kg、红花25kg、重楼25kg;
S2:取步骤S1称量好的当归及姜黄药材,粉碎成10目后,投入多功能提取罐内,加4倍量水浸泡3h,-0.06Mpa压力下72℃蒸馏至无挥发油产生,收集挥发油;
S3:取步骤S1称量好的其他药材投入到步骤S2的当归、姜黄药渣中,加水煎煮2次,第一次加原料组分总重量10倍量水,煎煮3h,第二次加过滤原料组分总重量9倍量水,煎煮2h,合并滤液;
S4:将步骤S3的滤液浓缩至相对密度在64℃为1.06的清膏,加入与清膏等量的95%乙醇,静置22h,滤取上清液回收乙醇浓缩至相对密度在64℃为1.09的浸膏;
S5:取步骤S2制得的挥发油加乙醇溶解后,搅拌35min,备用;
S6:取步骤S4制得的浸膏置于配料罐中,加入步骤S5的挥发油乙醇液,搅拌均匀,最后加水至配制量,搅拌25min,取出,100目滤布过滤,灭菌,装入经过灭菌的雾化喷头容器,即得。
实施例5
一种用于痛风、软组织损伤、风湿疼痛的制剂制备成喷剂的制备方法,包括以下步骤:
S1:按以下重量份称取原料:威灵仙30kg、两面针40kg、山慈菇20kg、三七30kg、当归40kg、姜黄80kg、栀子30kg、红花20kg、重楼20kg;
S2:取步骤S1称量好的当归及姜黄药材,粉碎成10目后,投入多功能提取罐内,加4倍量水浸泡2h,-0.07Mpa压力下70℃蒸馏至无挥发油产生,收集挥发油;
S3:取步骤S1称量好的其他药材投入到步骤S2的当归、姜黄药渣中,加水煎煮2次,第一次加原料组分总重量9倍量水,煎煮3h,第二次加过滤原料组分总重量8倍量水,煎煮2h,合并滤液;
S4:将步骤S3的滤液浓缩至相对密度在63℃为1.05的清膏,加入与清膏等量的95%乙醇,静置1h,滤取上清液回收乙醇浓缩至相对密度在63℃为1.08的浸膏;
S5:取步骤S2制得的挥发油加乙醇溶解后,搅拌30min,备用;
S6:取步骤S4制得的浸膏置于配料罐中,加入步骤S5的挥发油乙醇液,搅拌均匀,最后加水至配制量,搅拌30min,取出,100目滤布过滤,灭菌,装入经过灭菌的雾化喷头容器,即得。
二、临床应用试验
1.治疗痛风性关节炎
1.1病例选择
1.1.1诊断标准
参照1977年美国风湿病协会痛风诊断标准:
(1)滑囊液检查见特异性尿酸盐结晶体。
(2)痛风石用化学方法或偏振光显微镜观察证实含有尿酸盐结晶。
(3)1次以上的急性关节炎发作;炎症表现在1d内达到高峰;单关节炎发作;患病关节皮肤呈暗红色;第1跖趾关节疼痛或肿胀;单侧发作累及第1跖趾关节;单侧发作累及跗骨关节;有可疑的痛风石;高尿酸血症;X线检查见关节非对称性肿大;X线检查见骨皮质下囊肿不伴有骨质糜烂;关节炎症状发作期间关节液微生物培养阴性。
符合(1)或(2)或(3)中的6项者即可确诊为痛风性关节炎。
1.1.2纳入标准
(1)凡符合痛风诊断标准的患者;
(2)自愿接受1周治疗,并签订知情同意书的患者;
(3)年龄20-70岁;
(4)治疗前未服药激素及相关止痛药物的患者。
1.1.3排除标准
(1)不符合诊断标准的患者;
(2)有较严重皮肤过敏者;
(3)合并心、脑、肝、肾和造血系统等严重疾病者。
(4)评估后预计依从性差者;
(5)晚期关节重度畸形、僵硬、丧失劳动力者。
1.2观察指标
(1)关节疼痛指数,采用视觉模拟评分法(VAS),满分为10分,得分越低,情况越好;
(2)关节活动度,采用4分评分法。0分,正常;1分,轻度,活动时疼痛,但仍可进行正常活动;2分,中度,活动是疼痛明显加重,影响工作,生活自理;3分,重度,活动时疼痛难忍,卧床,生活不能自理;
(3)关节红肿程度,采用4分评分法。0分,正常,无红肿;1分,轻度,局部皮肤微红;2分,中度,局部皮肤发红发热,关节较发病前稍肿;3分,重度,局部皮肤明显发红发热,关节明显肿胀。
1.3疗效评定标准
依据《中药新药临床研究指导原则》中痛风的疗效评定标准评定疗效。
(1)痊愈:症状完全消失,关节功能恢复正常,主要化验指标正常;
(2)显效:主要症状消失,关节功能基本恢复,主要化验指标基本正常;
(3)有效:主要症状基本消失,主要关节功能及主要化验指标有所改善;
(4)无效:与治疗前相比各方面均无明显改善。
1.4给药方法
将符合上述病例标准患者165例(均为男性,平均年龄48岁,病程3个月-10年)随机分成3个组,每组55人。
试验组:给予本发明实施例5的样品,喷于关节肿痛处,每天2-3次,连续用3-4周。
对照组:(1)口服市售秋水仙碱片,按说明书使用,连续用3-4周;
(2)给予市售痛风散外敷,按说明书使用,连续用3-4周。
1.5结果
1.5.1治疗前后观察指标情况
结果见表1。
表1治疗前后观察指标情况比较(x±s)
注:与本组治疗前比较,aP<0.01;与对照组治疗后比较,bP<0.01。
由表1可以看出,三组患者治疗后关节疼痛指数、关节活动度和关节肿胀积分均有明显下降,治疗组降低程度优于对照组,差异有统计学意义(P<0.01)。
1.5.2临床治疗效果
结果见表2。
表2治疗痛风性关节炎临床试验结果表
在以上试验过程中,试验组中无一例患者出现不良反应,而对照组(2)中有29例患者出现不同程度的腹痛、腹泻、食欲减退等不良反应,对照组(2)有1例患者出现皮肤过敏、红肿现象。
由表2可知,本发明实施例5对痛风性关节治疗的总有效率为94.5%,高于对照组,而且在试验过程中未出现任何不良反应,说明本发明的制剂可有效治疗痛风性关节炎,使用安全有效。以下是几个典型的例子:
典型例子1:胡某,男,46岁,患痛风2年,夜间常因跖趾关节剧痛而惊醒,呈撕裂样,白天也疼痛难忍,周围组织也出现红、肿、热、痛等现象。使用本发明实施例5样品14天后,红、肿、热、痛症状减轻,再连续用14天后,红、肿、热、痛症状消失。连续复查3个月没有发现复发。
典型例子2:王某,男,51岁。患痛风3年,自发病以来,右侧大拇趾间断红肿疼痛难忍,烦躁,行走困难,夜间疼痛加重,呈刀割样,经常睡中被惊醒,观察患趾暗红浮肿波及足背,触之灼热疼痛拒按。使用本发明实施例5的产品21天后,肿痛明显减轻,再使用7天后,右拇趾红肿疼痛消失,半年未复发。
2.治疗软组织损伤
2.1病例选择
2.1.1诊断标准
依据《中药新药临床研究指导原则》中有关急性软组织挫伤和关节扭伤诊断标准:有明显的外伤史或关节扭伤史;损伤局部疼痛、肿胀、瘀斑或皮下血肿,压痛;肢体功能或关节功能障碍;X线检查无骨折、脱位及骨骼系统疾病等。
2.1.2纳入标准
(1)符合上述急性踝关节软组织的诊断标准,损伤时间小于3d者;
(2)无神经、血管损伤,皮肤保持完整;
(3)无重要器官脏器的损伤,如心、肝、肾的损伤,无循环、呼吸、消化、造血系统疾病以及精神病、结核、肿瘤等疾病;
(4)未用过其他治疗急性软组织损伤的药物;
(5)年龄在18-70周岁之间;
(6)知情同意,并签知情同意书。
2.1.3排除标准
(1)年龄在18岁以下或70岁以上;
(2)妊娠或哺乳期妇女、过敏体质者;
(3)骨折或肌肉、肌腱、韧带等软组织完全断裂者;
(4)肝肾功能异常者,合并肝、肾等重要脏器疾病,循环、呼吸、泌尿、造血、内分泌系统等严重原发性疾病及精神病患者。
2.2疗效评定标准
(1)痊愈:红、肿、热、痛消失,所附着或邻近关节活动自如;
(2)显效:红、肿、热消失,略有酸痛,所附着或邻近关节活动基本不受限;
(3)有效:红、肿、热、痛减轻,所附着或邻近关节活动轻度受限;
(4)无效;红、肿、热、痛无改善,关节活动受限。
2.3给药方法
将符合上述病例标准患者128例(其中男78例,女45例,平均年龄43岁)随机分成2个组,每组64人。
试验组:给予本发明实施例5样品,喷于患处,每天2-3次,根据患者损伤的具体情况,外用绷带包扎固定或加用支具关节外固定,连续用2周。
对照组:使用市售伤痛灵喷雾剂,按说明书使用,连续用2周;
2.4结果
结果详见表3。
表3治疗软组织损伤临床试验结果表
在以上试验过程中,试验组中无一例患者出现不良反应,而对照组中有2例患者出现不同程度皮肤瘙痒、潮红等过敏反应。
由表3可知,本发明实施例5的产品对软组织损伤治疗的总有效率为100%,高于对照组,而且在试验过程中未出现任何不良反应,说明本发明的制剂可有效治疗软组织损伤,使用安全有效。以下为典型的例子:
典型例子1:卢某,男,48岁,因手关节扭伤,关节疼痛、肿胀,伴有皮下血肿,压痛;手臂关节活动功能障碍;X线检查无骨折、脱位。使用本发明实施例5样品14天后,上述症状消失,手臂关节活动自如,痊愈。
典型例子2:张某,女,52岁,腿膝盖部碰撞硬物受伤,局部疼痛、肿胀、瘀斑,压痛;腿膝盖关节活动功能障碍;X线检查无骨折、脱位。使用本发明实施例5样品7天后,上述症状减轻,再使用7天后,症状消失,痊愈。
3.治疗风湿疼痛
3.1病例选择
选择风湿性关节炎患者。
3.2疗效评定标准
(1)痊愈:关节疼痛症状已经完全消失,没有出现运动障碍及功能性损伤现象,已经可以恢复正常工作和生活状态;
(2)显效:疼痛症状已经明显好转,可以从事一些较轻的工作;
(3)有效:存在疼痛症状,但疼痛程度与治疗前比较有所改善,对正常工作和生活会产生一定的影响;
(4)无效:临床症状表现没有任何改善。
3.3给药方法
将符合上述病例标准患者159例(其中男97例,女62例,平均年龄52岁,病程5个月-12年)随机分成3个组,每组53人。
试验组:
给予本发明实施例5样品,喷于关节肿痛处,每天2-3次,连续用30天。
对照组:(1)口服市售舒林酸片,每次0.2g,每天2次;口服市售甲氨蝶呤片,每次10mg,每星期1次;口服市售柳氮磺吡啶胶囊,每次0.75g,每天3次,连续服用30天;
(2)给予市售风湿痛喷剂,按说明书使用,连续用30天。
3.4结果
结果见表4。
表4治疗风湿性关节炎临床试验结果表
在以上试验过程中,试验组中无一例患者出现不良反应,而对照组(2)中有18例患者出现口腔炎、皮疹、恶心、食欲不振、头痛等不良反应,对照组(2)有2例患者出现皮肤瘙痒、红肿等过敏现象。
由表4可知,本发明实施例5对风湿性关节治疗的总有效率为92.4%,高于对照组,而且在试验过程中未出现任何不良反应,说明本发明的制剂可有效治疗风湿性关节炎,使用安全有效。以下是典型的例子:
典型例子1:赵某,男,62岁,患风湿病5年,症状表现为关节红、肿、热、痛明显,不能活动,发病部位为膝、踝、肩、腕关节,是疼痛游走不定且持续时间不长,几天后可自行消退,偶尔伴有中度发热。使用本发明实施例5样品20天后,红、肿、热、痛症状减轻,再使用10天后,红、肿、热、痛症状消失,痊愈,1年后不复发。
典型例子2:苏某,女,65岁。患痛风2年,自发病以来,膝、髋、踝下肢关节以及肩、肘关节红、肿、热、痛,关节活动障碍,疼痛游走不定,持续时间不长,可自行消退。使用本发明实施例5的产品30天后,红、肿、热、痛症状消失,痊愈,1年半后不复发。
以上内容不能认定本发明的具体实施只局限于这些说明,对于本发明所属技术领域的普通技术人员来说,在不脱离本发明构思的前提下,还可以做出若干简单推演或替换,都应当视为属于本发明由所提交的权利要求书确定的专利保护范围。
Claims (10)
1.一种用于痛风、软组织损伤、风湿疼痛的制剂,其特征在于,包括以下重量份的原料:威灵仙20-40份、两面针20-60份、山慈菇10-30份、三七20-40份、当归20-60份、姜黄60-100份、栀子20-40份、红花10-30份、重楼10-30份。
2.根据权利要求1所述的用于痛风、软组织损伤、风湿疼痛的制剂,其特征在于,包括以下重量份的原料:威灵仙25-35份、两面针30-50份、山慈菇15-25份、三七25-35份、当归30-50份、姜黄70-90份、栀子25-35份、红花15-25份、重楼15-25份。
3.根据权利要求2所述的用于痛风、软组织损伤、风湿疼痛的制剂,其特征在于,包括以下重量份的原料:威灵仙30份、两面针40份、山慈菇20份、三七30份、当归40份、姜黄80份、栀子30份、红花20份、重楼20份。
4.根据权利要求1-3任一项所述的用于痛风、软组织损伤、风湿疼痛的制剂,其特征在于,所述制剂制备成喷剂、搽剂、酊剂。
5.根据权利要求1-3任一项所述的用于痛风、软组织损伤、风湿疼痛的制剂,其特征在于,所述制剂制备成喷剂。
6.一种根据权利要求5所述的用于痛风、软组织损伤、风湿疼痛的制剂制备成喷剂的制备方法,其特征在于,包括以下步骤:
S1:按以下重量份称取原料:威灵仙20-40份、两面针20-60份、山慈菇10-30份、三七20-40份、当归20-60份、姜黄60-100份、栀子20-40份、红花10-30份、重楼10-30份;
S2:取步骤S1称量好的当归及姜黄药材,粉碎成10目后,投入多功能提取罐内,加3-5倍量水浸泡2-3h,减压蒸馏至无挥发油产生,收集挥发油;
S3:取步骤S1称量好的其他药材投入到步骤S2的当归、姜黄药渣中,加原料组分总重量的5-10倍量水,煎煮2-3次,每次1-3h,过滤,合并滤液;
S4:将步骤S3的滤液浓缩至相对密度在60-65℃为1.03-1.07的清膏,加入与清膏等量的95%乙醇,静置,滤取上清液回收乙醇浓缩至相对密度在60-65℃为1.05-1.10的浸膏;
S5:取步骤S2制得的挥发油加乙醇溶解后,搅拌20-40min,备用;
S6:取步骤S4制得的浸膏置于配料罐中,加入步骤S5的挥发油乙醇液,搅拌均匀,最后加水至配制量,搅拌20-30min,取出,过滤,灭菌,装入经过灭菌的雾化喷头容器,即得。
7.根据权利要求6所述的用于痛风、软组织损伤、风湿疼痛的制剂制备成喷剂的制备方法,其特征在于:步骤S2所述减压蒸馏温度为60-75℃,压力为(-0.06MPa)-(-0.08Mpa)。
8.根据权利要求6所述的用于痛风、软组织损伤、风湿疼痛的制剂制备成喷剂的制备方法,其特征在于:步骤S4所述加入乙醇后静置时间为18-24h。
9.根据权利要求6所述的用于痛风、软组织损伤、风湿疼痛的制剂制备成喷剂的制备方法,其特征在于:步骤S6所述过滤步骤用100目滤布过滤。
10.根据权利要求1-3任一项所述的用于痛风、软组织损伤、风湿疼痛的制剂,其特征在于,所述制剂在制备用于痛风、软组织损伤、风湿疼痛的药物中的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710408826.5A CN107158322A (zh) | 2017-06-02 | 2017-06-02 | 一种用于痛风、软组织损伤、风湿疼痛的制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710408826.5A CN107158322A (zh) | 2017-06-02 | 2017-06-02 | 一种用于痛风、软组织损伤、风湿疼痛的制剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107158322A true CN107158322A (zh) | 2017-09-15 |
Family
ID=59824485
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710408826.5A Pending CN107158322A (zh) | 2017-06-02 | 2017-06-02 | 一种用于痛风、软组织损伤、风湿疼痛的制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107158322A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114099627A (zh) * | 2021-12-07 | 2022-03-01 | 广西大海阳光药业有限公司 | 一种活血通络用抑菌喷剂的制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106729375A (zh) * | 2016-12-09 | 2017-05-31 | 广西健铧健康产业有限公司 | 一种治疗痛风、跌打损伤、关节痛的中药组合物 |
-
2017
- 2017-06-02 CN CN201710408826.5A patent/CN107158322A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106729375A (zh) * | 2016-12-09 | 2017-05-31 | 广西健铧健康产业有限公司 | 一种治疗痛风、跌打损伤、关节痛的中药组合物 |
Non-Patent Citations (1)
Title |
---|
都兴东等: "威驰搽剂对家兔皮肤刺激性研究", 《东南国防医药》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114099627A (zh) * | 2021-12-07 | 2022-03-01 | 广西大海阳光药业有限公司 | 一种活血通络用抑菌喷剂的制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102552637B (zh) | 治疗肩周炎的中药组合物及其制备方法 | |
CN109200144A (zh) | 一种中药组合物及其应用和膏药 | |
CN104258278B (zh) | 骨伤灵喷雾剂 | |
CN103751306A (zh) | 一种抗风湿消炎止痛药物组合物 | |
CN103768531B (zh) | 用于治疗类风湿关节炎的中药组合物及其制备方法 | |
CN104815318A (zh) | 一种治疗痛风的中药制剂 | |
CN104352901A (zh) | 一种治疗痛风的中药 | |
CN102302733B (zh) | 治疗卵巢囊肿的内服中药组合物 | |
CN103550345A (zh) | 一种治疗风湿疼痛的药酒 | |
CN106729379A (zh) | 一种治疗急性痛风性关节炎的外敷中药散剂及其制备方法 | |
CN107158322A (zh) | 一种用于痛风、软组织损伤、风湿疼痛的制剂及其制备方法 | |
CN103520291B (zh) | 一种治疗瘀滞型肩周炎的中药制剂及其制备方法 | |
CN106309849A (zh) | 一种足浴用藏药组合物及其应用 | |
CN108785421B (zh) | 一种用于治疗骨折的中药配方及其制法 | |
CN100444871C (zh) | 治疗风湿、类风湿的全无毒中药组合物 | |
CN104056231B (zh) | 一种配合西医治疗老年性皮肤瘙痒症的中药组合物 | |
CN102872252A (zh) | 一种治疗风湿疼痛的药物组合物 | |
CN102872287A (zh) | 一种治疗股骨头坏死的中药组合物及其制备方法 | |
CN106924673A (zh) | 一种治疗骨质增生的中药组合物及其药剂制备方法 | |
CN101703626B (zh) | 一种治疗风湿性关节炎的药物 | |
CN106177859A (zh) | 一种治疗风湿骨痛的药酒及其制备方法 | |
CN104771529A (zh) | 一种治疗肝肾亏虚型创伤性关节炎的药物及制备方法 | |
CN104887852A (zh) | 一种治疗血虚型产后风的中药及制备方法 | |
CN105079697A (zh) | 一种治疗风湿性心脏病的中药组合物及其制备方法 | |
CN103877500A (zh) | 一种治疗风寒湿邪所致诸症的药酒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170915 |
|
RJ01 | Rejection of invention patent application after publication |